Literature DB >> 17478639

Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Stephan Mielke1, Katayoun Rezvani, Bipin N Savani, Raquel Nunes, Agnes S M Yong, John Schindler, Roger Kurlander, Victor Ghetie, Elizabeth J Read, Scott R Solomon, Ellen S Vitetta, A John Barrett.   

Abstract

Selective depletion (SD) of host-reactive donor T cells from allogeneic stem-cell transplants (SCTs) using an anti-CD25 immunotoxin (IT) is a strategy to prevent acute graft-versus-host disease (aGvHD). There is concern that concurrent removal of regulatory T cells (T(regs)) with incomplete removal of alloactivated CD25(+) T cells could increase the risk of aGvHD. We therefore measured T(regs) in the blood of 16 patients receiving a T-cell-depleted allograft together with anti-CD25-IT-treated SD lymphocytes, in 13 of their HLA-identical donors, and in 10 SD products. T(regs) were characterized by intracellular staining for forkhead box protein 3 (FOXP3) and by quantitative reverse-transcription-polymerase chain reaction (qRT-PCR) for FOXP3 gene in CD4(+) cells. Patients received a median of 1.0 x 10(8)/kg SD T cells and a stem cell product containing a median of 0.25 x 10(4)/kg residual T cells. T(regs) reconstituted promptly after SCT and underwent further expansion. Of the CD4(+) T cells in SD products, 1.5% to 4.8% were CD25(-) T(regs). Acute GvHD (>or= grade II) was restricted to 5 patients whose donors had significantly (P = .019) fewer T(regs) compared with those without clinically significant aGvHD. These results suggest that rapid T(reg) reconstitution can occur following SD allografts, either from CD25(-) T(regs) escaping depletion, or from residual CD25(-) and CD25(+) T(regs) contained in the stem-cell product that expand after transplantation and may confer additional protection against GvHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478639      PMCID: PMC1975850          DOI: 10.1182/blood-2007-03-079160

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.

Authors:  B R Blazar; C J Lees; P J Martin; R J Noelle; B Kwon; W Murphy; P A Taylor
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).

Authors:  B Fehse; O Frerk; M Goldmann; M Bulduk; A R Zander
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

3.  Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell.

Authors:  Patricia A Taylor; Thea M Friedman; Robert Korngold; Randolph J Noelle; Bruce R Blazar
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.

Authors:  Udo F Hartwig; Michael Robbers; Claudia Wickenhauser; Christoph Huber
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

6.  Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.

Authors:  Benny J Chen; Xiuyu Cui; Congxiao Liu; Nelson J Chao
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

7.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study.

Authors:  Isabelle André-Schmutz; Françoise Le Deist; Salima Hacein-Bey-Abina; Ellen Vitetta; John Schindler; Gaelle Chedeville; Etienne Vilmer; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.

Authors:  Martin Guimond; Antonia Balassy; Mélanie Barrette; Sylvie Brochu; Claude Perreault; Denis Claude Roy
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Functional assessment and specific depletion of alloreactive human T cells using flow cytometry.

Authors:  Sergio L R Martins; Lisa S St John; Richard E Champlin; Eric D Wieder; John McMannis; Jeffrey J Molldrem; Krishna V Komanduri
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  32 in total

1.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

2.  Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuyuki Murase; Haesook T Kim; O R Gregory Bascug; Yutaka Kawano; Jeremy Ryan; Ken-ichi Matsuoka; Matthew S Davids; John Koreth; Vincent T Ho; Corey Cutler; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Anthony Letai; Jerome Ritz
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

Review 3.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

5.  High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.

Authors:  S-Y Lu; K-Y Liu; D-H Liu; L-P Xu; X-J Huang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

Review 6.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 7.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

8.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

9.  Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes.

Authors:  B G Engelhardt; M Jagasia; B N Savani; N L Bratcher; J P Greer; A Jiang; A A Kassim; P Lu; F Schuening; S M Yoder; M T Rock; J E Crowe
Journal:  Bone Marrow Transplant       Date:  2010-05-31       Impact factor: 5.483

10.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.